HALIFAX, NS, May 26 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development company, announced a research partnership with FIT Biotech, a Finland-based, clinical stage company that develops DNA vaccines. This research will formulate FIT Biotech's GTU(R) MultiHIV DNA plasmid with IVT's DepoVax(TM) vaccine delivery system to advance a therapeutic HIV vaccine.
"DepoVax(TM) will act as a vector to deliver FIT Biotech's GTU(R) MultiHIV DNA vaccine and our goal is to develop a more sophisticated and efficient HIV vaccine candidate," commented Dr. Marc Mansour, Vice President R&D at IVT.
The development of an HIV vaccine is complicated by the ability of the virus to mutate rapidly. FIT Biotech has addressed this challenge by designing a synthetic DNA plasmid, known as GTU(R) MultiHIV that covers the antigenic variability within HIV strains. GTU(R) MultiHIV and is comprised of the multi-epitope/multivalent HIV antigens. As FIT Biotech's lead vaccine candidate, GTU(R) MultiHIV has the potential to trigger an immune response that slows the progression of HIV in infected individuals.
IVT's pre-clinical research demonstrates that DepoVax(TM) effectively delivers DNA plasmids into draining lymph nodes with as little as one dose. The DepoVax(TM) platform uses liposomes to encapsulate a target antigen, like GTU(R) MultiHIV, and adjuvant. DepoVax(TM) also relies on a hydrophobic carrier to create a depot effect that significantly enhances vaccine induced cell-mediated and humoral immunity.
This pre-clinical research partnership will combine the complementary technologies of DepoVax(TM) and GTU(R) MultiHIV. Both IVT and FIT Biotech will examine the novel vaccine's capabilities of inducing cell-mediated and humoral immunity against HIV virus.
"By testing DepoVax(TM) in combination with GTU(R) MultiHIV plasmid, we are working towards developing a superior vaccine candidate for therapeutic use against HIV a
|SOURCE ImmunoVaccine Technologies Inc.|
Copyright©2009 PR Newswire.
All rights reserved